MedTrace Logo

BDNF Gene Polymorphism and Antidepressants Treatment

NCT00308893 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2025-12-23

No results posted yet for this study

Summary

The main hypothesis is that the therapeutic response and pharmacological resistance to ADs in depressed patients can be associated with a polymorphism for the BDNF gene. The research of allelic forms associated to lesser efficiency or inefficiency of ADs could add to the body of evidence that BDNF mediates the mechanism of action of ADs, and could have important practical implications. We propose to compare in a group of patients with major depression, the allelic variability of the BDNF gene between responders and non-responders after a 3-week period and a 6-week period of SSRI treatment.

Conditions

Interventions

GENETIC

Genetic analysis

Compare BDNF polymorphism among responders and non-responders

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Wissam EL HAGE, MD, PhD · UNIVERSITY HOSPITAL OF TOURS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00308893 on ClinicalTrials.gov